A patient who is a known case of atherosclerosis underwent a circumflex artery bypass. The stent is now placed successfully. He's already taking lisinopril, verapamil, metoprolol. Which drug should be added?

Explanation

## Correct Answer: A. P2Y12 receptor blocker After coronary stent placement, dual antiplatelet therapy (DAPT) is the gold standard to prevent stent thrombosis and restenosis. The patient is already on lisinopril (ACE inhibitor), verapamil (calcium channel blocker), and metoprolol (beta-blocker)—all cardioprotective agents but none provide antiplatelet coverage. A P2Y12 receptor blocker (clopidogrel, prasugrel, or ticagrelor) must be added alongside aspirin (which should already be initiated at the time of stenting) to inhibit platelet aggregation via different mechanisms. Clopidogrel is the most commonly used P2Y12 inhibitor in India due to cost-effectiveness and established safety in post-stent patients. The combination of aspirin + P2Y12 blocker reduces the risk of stent thrombosis by ~50% compared to aspirin alone. Duration of DAPT is typically 12 months for acute coronary syndrome and 6 months for stable CAD post-stent, as per Indian guidelines and international consensus. This is a direct application of post-PCI management protocols taught in cardiology across Indian medical schools. ## Why the other options are wrong **B. Direct oral anticoagulant** — DOACs (apixaban, rivaroxaban) are indicated for atrial fibrillation or venous thromboembolism, not routine post-stent care. While anticoagulation may be considered in specific high-risk scenarios (e.g., left ventricular thrombus, mechanical prosthesis), they are NOT first-line after coronary stent placement. Adding DOAC without clear indication increases bleeding risk without additional stent protection benefit. **C. PDE 5 inhibitor** — PDE 5 inhibitors (sildenafil, tadalafil) are used for erectile dysfunction and pulmonary hypertension, not for antiplatelet or anticoagulant effects. They have no role in preventing stent thrombosis or restenosis. This is a distractor that tests knowledge of drug classes and their specific indications in cardiology. **D. PDE 3 inhibitor** — PDE 3 inhibitors (milrinone, cilostazol) have inotropic and vasodilatory properties but are not standard post-stent therapy. Cilostazol has mild antiplatelet effects but is inferior to P2Y12 blockers and is not recommended as monotherapy or as an adjunct to DAPT in Indian or international guidelines for post-stent management. ## High-Yield Facts - **Dual antiplatelet therapy (DAPT)** = aspirin + P2Y12 blocker is mandatory after coronary stent placement to prevent stent thrombosis. - **Clopidogrel** is the most cost-effective P2Y12 inhibitor in India; prasugrel and ticagrelor are alternatives with faster onset but higher cost. - **Duration of DAPT**: 12 months for acute coronary syndrome, 6 months for stable CAD post-stent (per Indian cardiology guidelines). - **Stent thrombosis risk** is reduced by ~50% with DAPT vs. aspirin monotherapy, with peak risk in first 30 days. - **P2Y12 blockers work** by inhibiting ADP-mediated platelet aggregation, complementing aspirin's COX-1 inhibition for synergistic antiplatelet effect. ## Mnemonics **DAPT After Stent** **D**ual **A**ntiplatelet **T**herapy = **A**spirin + **P**2Y12 blocker (Clopidogrel/Prasugrel/Ticagrelor). Remember: Two drugs, two mechanisms, one goal—prevent stent thrombosis. **P2Y12 Blockers in India** **C**lopidogrel (cheap, common), **P**rasugrel (potent, pricey), **T**icagrelor (top-tier, too costly). Use ClopidogrelFirst in resource-limited settings; switch to prasugrel/ticagrelor only in high-risk ACS. ## NBE Trap NBE pairs post-stent management with anticoagulation (DOAC option) to trap students who confuse antiplatelet therapy with anticoagulation—a common misconception in Indian medical education where both concepts are taught together in thrombosis modules. ## Clinical Pearl In Indian practice, a patient presenting with stent thrombosis often has poor DAPT adherence due to cost or side effects (e.g., clopidogrel-induced diarrhea). Always counsel on the 6–12 month commitment and consider switching P2Y12 blockers if intolerance occurs, rather than stopping DAPT prematurely. _Reference: Harrison Ch. 297 (Acute Coronary Syndromes); Robbins Ch. 11 (Hemostasis & Thrombosis); Indian Cardiology Society Guidelines on PCI and Stent Management_